Product image of Ivabradine Anpharm (Ivabradine) supplied by GNH India

Ivabradine Anpharm

Active Ingredient:
Ivabradine
Origin:
EU

Ivabradine Anpharm (Ivabradine)

Ivabradine, the active ingredient in Ivabradine Anpharm, is a selective If channel inhibitor presented as an oral formulation for oral administration. It is indicated for the management of chronic heart failure (NYHA class II–III) with reduced ejection fraction and for stable angina pectoris in adult patients.

GNH India supplies Ivabradine Anpharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand consistently.

Manufacturer / TM Owner

Anpharm Przedsiębiorstwo Farmaceutyczne Spółka Akcyjna

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Ivabradine is used to manage cardiovascular conditions that involve elevated heart rate.

  • Chronic heart failure (NYHA class II–III) with reduced ejection fraction: reduces heart rate, improving ventricular filling and symptoms.
  • Stable angina pectoris: lowers heart rate, decreasing myocardial oxygen demand and relieving angina.
  • Coronary artery disease with symptomatic angina: helps improve exercise capacity by controlling heart rate.

How It Works

  • Ivabradine selectively binds to the funny (If) current channels in the sino‑atrial node, inhibiting the inward sodium‑potassium current that drives spontaneous depolarization. This action slows the pacemaker activity, producing a dose‑dependent reduction in heart rate without affecting myocardial contractility, ventricular repolarisation, or systemic blood pressure.

Side Effects

Common Side Effects

  • Bradycardia: resting heart rate may fall below the intended range.
  • Visual disturbances (phosphenes): transient luminous phenomena, especially in low‑light conditions.
  • Headache: mild to moderate intensity, often transient.
  • Dizziness or vertigo: related to reduced heart rate or blood pressure changes.
  • Fatigue or general weakness: may accompany heart‑rate lowering.
  • Blurred vision: occasional, usually resolves with continued use.

Serious or Rare Side Effects

  • Symptomatic bradycardia requiring medical intervention.
  • Atrial fibrillation or other serious arrhythmias.
  • Severe hypotension leading to syncope.
  • High‑grade atrioventricular block.
  • Severe visual impairment or persistent phosphene phenomena.
  • Allergic reactions such as rash, angioedema, or anaphylaxis.

Precautions & Warnings

Before initiating therapy, consider the following precautions:

  • Cardiac monitoring: assess baseline heart rate and rhythm.
  • Hepatic impairment: avoid or adjust dose in severe liver disease.
  • Sick sinus syndrome or atrioventricular block: contraindicated unless a pacemaker is present.
  • Concomitant CYP3A4 inhibitors: avoid strong inhibitors to prevent excess exposure.
  • Pregnancy and lactation: safety not established; use only if clearly needed.
  • Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Ivabradine may interact with several medicines.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase ivabradine plasma levels.
  • Co‑administration with other heart‑rate lowering agents (beta‑blockers, digoxin): risk of excessive bradycardia.
  • Other If channel inhibitors (e.g., ranolazine): additive effect on heart‑rate reduction.

Moderate Interactions (Monitor Closely)

  • Moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil): may require dose adjustment.
  • QT‑prolonging drugs: monitor ECG for additive prolongation.
  • Antihypertensives: enhanced hypotensive effect may occur, requiring blood pressure monitoring.

Frequently Asked Questions

Ivabradine Anpharm is prescribed to lower heart rate in adults with chronic heart failure (NYHA class II–III) that has a reduced ejection fraction, and in patients with stable angina pectoris. By reducing the heart rate, it helps improve cardiac efficiency and relieve angina symptoms.

Ivabradine selectively inhibits the funny (If) current in the sino‑atrial node, the pacemaker of the heart. This inhibition slows the spontaneous depolarisation of pacemaker cells, leading to a controlled reduction in heart rate without affecting the strength of cardiac contraction.

The dose of ivabradine is individually determined by the prescribing clinician based on the patient’s heart‑rate, clinical condition, and response to therapy. The prescriber will select the appropriate strength, frequency, and any necessary titration schedule.

Safety data for ivabradine in pregnancy and lactation are limited. It is generally advised to avoid use unless the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the Ivabradine Anpharm product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any required import documentation.

Both ivabradine and beta‑blockers lower heart rate, but they act via different mechanisms. Beta‑blockers reduce heart rate by blocking adrenergic receptors and also lower blood pressure, whereas ivabradine selectively inhibits the If current without affecting contractility or blood pressure. Ivabradine may be used when beta‑blockers are contraindicated or not tolerated.

Store Ivabradine Anpharm at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Ivabradine Anpharm is taken orally, usually with or without food, as directed by the prescribing physician. The tablets should be swallowed whole with a glass of water and not chewed or crushed.

The most serious risks include symptomatic bradycardia, atrial fibrillation, severe hypotension, high‑grade atrioventricular block, and rare but significant visual disturbances. Patients should report any episodes of dizziness, fainting, palpitations, or persistent visual changes to their healthcare provider promptly.

Ivabradine should be avoided in patients with severe hepatic impairment, sick sinus syndrome, second‑ or third‑degree atrioventricular block (unless a pacemaker is present), uncontrolled hypotension, or in those taking strong CYP3A4 inhibitors. It is also contraindicated in individuals with known hypersensitivity to the drug.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ivabradine

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT